Table 5.

Results for univariable and multivariable Cox regression analysis for DD

DDOSHemEFSVGHR rate
HR95% CIPHR95% CIPHR95% CIP
Univariable analysis          
 dFLC >180 mg/L 3.39 1.86-6.18 .0001 2.05 1.24-3.36 .0048 0.27 0.11-0.65 .0046 
 ACR >220 mg/mmol 1.58 0.87-2.87 .13 2.21 1.33-3.66 .0021 0.39 0.17-0.91 .032 
 NT-ProBNP >8500 ng/L 5.57 3.01-10.3 <.0001 2.52 1.50-4.21 .0005 0.64 0.26-1.52 .31 
 eGFR <50 mL/min/1.73 m2 2.38 1.27-4.45 .0066 1.83 1.10-3.05 .020 0.38 0.16-0.87 .024 
 Age, y 1.03 1.00-1.07 .034 1.00 0.98-1.03 .73 1.03 0.99-1.08 .16 
 Male 1.35 0.69-2.62 .38 0.70 0.42-1.17 .18 1.07 0.45-2.59 .88 
 No. of organs 1.08 0.83-1.40 .59 1.02 0.81-1.28 .86 1.05 0.71 to 1.58 .79 
 No. of previous therapies 1.02 0.82-1.25 .89 1.13 0.94-1.36 .19 0.94 0.69-1.26 .66 
 Refractory to last therapy 0.70 0.39-1.27 .24 1.25 0.75-2.07 .39 0.60 0.26-1.37 .23 
 Refractory to last PI 1.32 0.71-2.45 .39 1.53 0.91-2.60 .11 0.15 0.05-0.38 .0001 
 Translocation t(11;14) 0.54 0.27-1.06 .074 0.47 0.26-0.83 .0093 2.16 0.84-5.80 .12 
 Gain of 1q21 2.34 1.18-4.65 .015 1.95 1.09-3.51 .025 0.88 0.32-2.41 .80 
 Hyperdiploidy 2.95 1.31-6.63 .0089 2.43 1.20-4.94 .014 0.09 0.00-0.52 .026 
 MM high-risk aberrations 0.95 0.33-2.71 .92 1.82 0.81-4.09 .14 0.97 0.17-5.56 .97 
 Deletion 13q14 0.90 0.44-1.87 .78 1.43 0.79-2.58 .24 2.10 0.79-5.83 .14 
Multivariable analysis          
 dFLC >180 mg/L 4.21 2.26-7.83 <.0001 2.51 1.49-4.24 .0006 0.17 0.06-0.46 .0009 
 ACR >220 mg/mmol 1.36 0.65-2.84 .42 2.07 1.12-3.83 .020 0.47 0.16-1.34 .16 
 NT-ProBNP >8500 ng/L 5.78 2.94-11.35 <.0001 2.21 1.26-3.88 .0056 0.78 0.27-2.23 .65 
 eGFR <50 mL/min/1.73 m2 1.50 0.67-3.35 .32 1.08 0.57-2.05 .82 0.46 0.16-1.33 .15 
 Age, y 1.02 0.99-1.05 .14 1.00 0.97-1.02 .87 1.05 1.00-1.11 .05 
DDOSHemEFSVGHR rate
HR95% CIPHR95% CIPHR95% CIP
Univariable analysis          
 dFLC >180 mg/L 3.39 1.86-6.18 .0001 2.05 1.24-3.36 .0048 0.27 0.11-0.65 .0046 
 ACR >220 mg/mmol 1.58 0.87-2.87 .13 2.21 1.33-3.66 .0021 0.39 0.17-0.91 .032 
 NT-ProBNP >8500 ng/L 5.57 3.01-10.3 <.0001 2.52 1.50-4.21 .0005 0.64 0.26-1.52 .31 
 eGFR <50 mL/min/1.73 m2 2.38 1.27-4.45 .0066 1.83 1.10-3.05 .020 0.38 0.16-0.87 .024 
 Age, y 1.03 1.00-1.07 .034 1.00 0.98-1.03 .73 1.03 0.99-1.08 .16 
 Male 1.35 0.69-2.62 .38 0.70 0.42-1.17 .18 1.07 0.45-2.59 .88 
 No. of organs 1.08 0.83-1.40 .59 1.02 0.81-1.28 .86 1.05 0.71 to 1.58 .79 
 No. of previous therapies 1.02 0.82-1.25 .89 1.13 0.94-1.36 .19 0.94 0.69-1.26 .66 
 Refractory to last therapy 0.70 0.39-1.27 .24 1.25 0.75-2.07 .39 0.60 0.26-1.37 .23 
 Refractory to last PI 1.32 0.71-2.45 .39 1.53 0.91-2.60 .11 0.15 0.05-0.38 .0001 
 Translocation t(11;14) 0.54 0.27-1.06 .074 0.47 0.26-0.83 .0093 2.16 0.84-5.80 .12 
 Gain of 1q21 2.34 1.18-4.65 .015 1.95 1.09-3.51 .025 0.88 0.32-2.41 .80 
 Hyperdiploidy 2.95 1.31-6.63 .0089 2.43 1.20-4.94 .014 0.09 0.00-0.52 .026 
 MM high-risk aberrations 0.95 0.33-2.71 .92 1.82 0.81-4.09 .14 0.97 0.17-5.56 .97 
 Deletion 13q14 0.90 0.44-1.87 .78 1.43 0.79-2.58 .24 2.10 0.79-5.83 .14 
Multivariable analysis          
 dFLC >180 mg/L 4.21 2.26-7.83 <.0001 2.51 1.49-4.24 .0006 0.17 0.06-0.46 .0009 
 ACR >220 mg/mmol 1.36 0.65-2.84 .42 2.07 1.12-3.83 .020 0.47 0.16-1.34 .16 
 NT-ProBNP >8500 ng/L 5.78 2.94-11.35 <.0001 2.21 1.26-3.88 .0056 0.78 0.27-2.23 .65 
 eGFR <50 mL/min/1.73 m2 1.50 0.67-3.35 .32 1.08 0.57-2.05 .82 0.46 0.16-1.33 .15 
 Age, y 1.02 0.99-1.05 .14 1.00 0.97-1.02 .87 1.05 1.00-1.11 .05 

HR, hazard ratio. Statistically significant results (P < .05) are bold.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal